期刊文献+

阻塞性睡眠呼吸暂停低通气综合征患者认知障碍的研究 被引量:7

The study of cognitive impairment in patients with obstructive sleep apnea and hypopnea syndrome
下载PDF
导出
摘要 目的应用蒙特利尔认知评估量表(Montreal cognitive assessment,MoCA)评估阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnea and hypopnea syndrom,OSAHS)患者的认知功能。方法 OSAHS男性患者82例,根据呼吸暂停低通气指数(apnea hypopnea index,AHI)和最低血氧饱和度(SaO2),分为轻度组31例、中度组25例、重度组26例;健康男性20例为对照组。应用MoCA对各组患者进行评分。结果对照组、轻度组与中、重度组MoCA总分、注意力、延迟回忆评分组间比较,差异均有统计学意义(P均<0.05)。对照组与重度组视空间与执行功能、定向比较差异有统计学意义(P均<0.05),对照组与轻度组注意力差异有统计学意义(P<0.05);MoCA评分与SaO2呈正相关(P<0.01),与AHI、最长呼吸暂停时间(lon-gest apnea time,LAT)、血氧饱和度小于90%时间占睡眠时间百分比(saturation lower then 90%,SLT 90%)呈负相关(P<0.01)。结论 OSAHS患者出现轻度认知障碍风险增加;MoCA可以作为筛查OSAHS患者认知障碍的方法。 Objective To assess cognitive impairment of patients with obstructive sleep apnea and hypopnea syndrome(OSAHS) by montreal cognitive assessment(MoCA).Methods Eighty two OSAHS patients were divided into three groups according to apnea hypopnea index(AHI) and longest apnea time(LAT),including mild group,moderate and severe groups.The cognitive function was evaluated by MoCA.Results The parameters,including total scores of MoCA,attention,delayed recall in moderate and severe groups were lower than mild or control group(P0.05).The visuospatial skills and orientation in severe groups were significantly lower than those in control group(P0.05).The attention in mild groups were lower than that in control group(P0.05).The total scores of MoCA were positive correlation with Minimal saturation of blood oxygen(P0.01),and were negative correlation with AHI,LAT,and percentage of time spend when oxygen saturation lower than 90%(SLT 90%)(P0.01).Conclusion The risk of MCI increased in OSAHS patients.MoCA could be used to evaluate the cognitive impairment in OSAHS patients.
作者 张文洛 冯博
出处 《海军总医院学报》 2011年第3期148-149,155,共3页 Journal of Naval General Hospital of PLA
关键词 阻塞性睡眠呼吸暂停低通气综合征 认知障碍 蒙特利尔认知评估量表 Obstructive sleep apnea and hypopnea syndrome Cognitive impairment Montreal cognitive assessment
  • 相关文献

参考文献7

  • 1Petersen RC.Mild cognitive impairment as a diagnostic entity[J].J Intern Med,2004,256(3):183-194.
  • 2Nasreddine ZS,Phillips NA,Bédirian V,et aL The Montreal Cognitive Assessment(MoCA):a brief screening tool for mild cognitive impairment[J].J Am Geriatr Soc,2005,53(4):695-699.
  • 3中华医学会呼吸病学分会睡眠呼吸疾病学组.阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案)[J].中华结核和呼吸杂志,2002,25(4):195-198. 被引量:1845
  • 4俞丽华.轻度认知损害[J].国际精神病学杂志,2011,38(1):39-44. 被引量:5
  • 5Schulz R,Seeger W,Fegbeutel C,et al.Changes in extracranial arteries in obstructive sleep apnoea[J].Eur Respir J,2005,25(1):69-74.
  • 6Tsai JC.Neurological and neurobehavioral sequelae of obstructive sleep apnea[J].NeuroRehabilitation,2010,26(1):85-94.
  • 7Lee JY,Dong Woo Lee,Cho SJ,et al.Brief screening for mild cognitive impairment in elderly outpatient clinic:validation of the korean version of the Montreal Cognitive Assessment[J].J Geriatr Psychiatry Neurol,2008,21(2):104-410.

二级参考文献14

  • 1Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow - up study. Lancet Neurol. 2006; 5:228-234.
  • 2Walker LC, Ibegbu CC, Todd CW, et al. Emerging prospects for the disease - modifying treatment of Mzheimer's disease. Biochem Pharmacol 2005; 69:1001 -1008.
  • 3Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus. J Intern Med. 2004 ; 256 : 240 - 246.
  • 4Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256 : 183 - 194.
  • 5Markesbery WR, Schmitt FA, Kryscio R J, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006; 63 : 38 -46.
  • 6Petersen RC, Parisi JE, Dickson DW, et al. Neuropathology of anmestic mild cognitive impairment. Arch Neurol. 2006; 63: 665 - 672.
  • 7Jicha GA, Parisi JE, Dickson DW, et al. Neuropathological outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006; 63:674-681.
  • 8Petersen RC, Thomas RG, Grundman M, et al. Donepezil and vitamin E in the treatment of mild cognitive impairment. N Engl J Med. 2005 ; 352 : 2379 -2388.
  • 9Gold M, Francke S, Nye JS, et al. Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment. Neurobiol Aging, 2004; 25:S521.
  • 10Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology, 2004; 62:1199 - 1201.

共引文献1848

同被引文献121

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部